This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ floxuridine,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Antineoplastic Activity: Floxuridine belongs to the class of medications known as antimetabolites. It works by interfering with the synthesis of DNA and RNA, which are essential for the growth and replication of cancer cells. By inhibiting nucleic acid synthesis, floxuridine prevents cancer cells from proliferating and induces their death.

  2. Treatment of Colorectal Cancer: Floxuridine is commonly used in the treatment of colorectal cancer, particularly when the cancer has spread to the liver (metastatic colorectal cancer). It may be administered directly into the hepatic artery (intra-arterial infusion) to target tumors in the liver.

  3. Administration Route: Floxuridine is typically administered as an intravenous infusion or through direct injection into the hepatic artery. In the case of hepatic artery infusion, floxuridine is delivered directly to the liver, allowing for higher concentrations of the drug to reach the tumor while minimizing systemic side effects.

  4. Adverse Effects: Common side effects of floxuridine may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and mucositis (inflammation of the mucous membranes). Bone marrow suppression, resulting in decreased production of blood cells (myelosuppression), may also occur, leading to anemia, leukopenia, and thrombocytopenia.

  5. Liver Toxicity: Floxuridine can cause hepatotoxicity (liver damage), particularly when administered via hepatic artery infusion. Hepatic artery occlusion or liver dysfunction may occur as a result of the infusion procedure, necessitating close monitoring of liver function during treatment.

  6. Hand-Foot Syndrome: Floxuridine may cause a side effect known as hand-foot syndrome (palmar-plantar erythrodysesthesia), characterized by redness, swelling, and pain in the palms of the hands and soles of the feet. This condition can be dose-limiting and may require dose adjustments or discontinuation of treatment.

  7. Bone Marrow Suppression: Floxuridine can suppress bone marrow function, leading to a decreased production of white blood cells, red blood cells, and platelets. This can increase the risk of infections, anemia, and bleeding, necessitating regular monitoring of blood cell counts during treatment.

  8. Contraindications and Precautions: Floxuridine is contraindicated in individuals with known hypersensitivity to the drug or its components. It should be used with caution in patients with preexisting liver disease or impaired bone marrow function. Pregnancy and breastfeeding are generally contraindicated due to the potential risk of harm to the fetus or infant.

  9. Monitoring and Supportive Care: Patients receiving floxuridine therapy require close monitoring of liver function, blood cell counts, and renal function. Supportive care measures, such as antiemetic medications to manage nausea and vomiting, may be prescribed to improve tolerance to treatment.

  10. Combination Therapy: Floxuridine may be used in combination with other chemotherapy drugs or radiation therapy as part of a multidisciplinary approach to cancer treatment. The choice of treatment regimen depends on factors such as the type and stage of cancer, as well as the patient's overall health and treatment goals.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of floxuridine,(prescription) On Probiotics

Rank Probiotic Impact
species Bacteroides uniformis Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces
species Parabacteroides distasonis Reduces

Bacteria Impacted by floxuridine,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Clostridium genus Decreases 👪 Source Study Pathogen
Streptococcus genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Lacrimispora genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Clostridium perfringens A no rank Decreases 👶 Source Study
Clostridium perfringens B no rank Decreases 👶 Source Study
Clostridium perfringens D no rank Decreases 👶 Source Study
Clostridium perfringens E no rank Decreases 👶 Source Study
Escherichia coli O1:K1:H7 no rank Decreases 👶 Source Study
Escherichia coli O139:H1 no rank Decreases 👶 Source Study
Escherichia coli O141:H4 no rank Decreases 👶 Source Study
Escherichia coli O145:H34 no rank Decreases 👶 Source Study
Escherichia coli O15:H12 no rank Decreases 👶 Source Study
Escherichia coli O155:H21 no rank Decreases 👶 Source Study
Escherichia coli O158:H23 no rank Decreases 👶 Source Study
Escherichia coli O16:H48 no rank Decreases 👶 Source Study
Escherichia coli O170:H18 no rank Decreases 👶 Source Study
Escherichia coli O18ac:H14 no rank Decreases 👶 Source Study
Escherichia coli O19:H7 no rank Decreases 👶 Source Study
Escherichia coli O2:K1:H4 no rank Decreases 👶 Source Study
Escherichia coli O2:K1:H5 no rank Decreases 👶 Source Study
Escherichia coli O2:K1:H7 no rank Decreases 👶 Source Study
Escherichia coli O20:H12 no rank Decreases 👶 Source Study
Escherichia coli O25:H16 no rank Decreases 👶 Source Study
Escherichia coli O55:H7 no rank Decreases 👶 Source Study
Escherichia coli O68:H12 no rank Decreases 👶 Source Study
Escherichia coli O7:H15 no rank Decreases 👶 Source Study
Escherichia coli O78:H51 no rank Decreases 👶 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Escherichia coli O84:H7 no rank Decreases 👶 Source Study
Escherichia coli O85:H1 no rank Decreases 👶 Source Study
Escherichia coli O121 serogroup Decreases 👶 Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O155 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O177 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O3 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O78 serogroup Decreases 👶 Source Study
Escherichia coli O86 serogroup Decreases 👶 Source Study
Escherichia coli O91 serogroup Decreases 👶 Source Study
Escherichia coli H20 serotype Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O1:HNT serotype Decreases 👶 Source Study
Escherichia coli O10:H32 serotype Decreases 👶 Source Study
Escherichia coli O100:H21 serotype Decreases 👶 Source Study
Escherichia coli O103:H2 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O111:H- serotype Decreases 👶 Source Study
Escherichia coli O111:H8 serotype Decreases 👶 Source Study
Escherichia coli O111:NM serotype Decreases 👶 Source Study
Escherichia coli O112ab:H8 serotype Decreases 👶 Source Study
Escherichia coli O112ac:H19 serotype Decreases 👶 Source Study
Escherichia coli O113:H21 serotype Decreases 👶 Source Study
Escherichia coli O114:H49 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O125ac:K+:H10 serotype Decreases 👶 Source Study
Escherichia coli O126:H45 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O128ac:H12 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O145:H25 serotype Decreases 👶 Source Study
Escherichia coli O145:H28 serotype Decreases 👶 Source Study
Escherichia coli O145:NM serotype Decreases 👶 Source Study
Escherichia coli O15:H18 serotype Decreases 👶 Source Study
Escherichia coli O150:H6 serotype Decreases 👶 Source Study
Escherichia coli O152:H23 serotype Decreases 👶 Source Study
Escherichia coli O157:H- serotype Decreases 👶 Source Study
Escherichia coli O157:H43 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O16:H6 serotype Decreases 👶 Source Study
Escherichia coli O167:H26 serotype Decreases 👶 Source Study
Escherichia coli O174:H21 serotype Decreases 👶 Source Study
Escherichia coli O176:H45 serotype Decreases 👶 Source Study
Escherichia coli O2:H6 serotype Decreases 👶 Source Study
Escherichia coli O2:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O25:H1 serotype Decreases 👶 Source Study
Escherichia coli O25:NM serotype Decreases 👶 Source Study
Escherichia coli O26:H11 serotype Decreases 👶 Source Study
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O45:H2 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O6:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O7:H4 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Escherichia coli O78:H4 serotype Decreases 👶 Source Study
Escherichia coli O8:H8 serotype Decreases 👶 Source Study
Escherichia coli O89m:H10 serotype Decreases 👶 Source Study
Escherichia coli O89m:H9 serotype Decreases 👶 Source Study
Escherichia coli O9:H10 serotype Decreases 👶 Source Study
Escherichia coli O99:H6 serotype Decreases 👶 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Streptococcus parasanguinis species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Bacteroides ovatus species Decreases 📓 Source Study
Mediterraneibacter gnavus species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Bacteroides xylanisolvens species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Eggerthella lenta species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Agathobacter rectalis species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases 👶 Source Study

Impact of floxuridine,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 3.4 0.5 5.8
Age-Related Macular Degeneration and Glaucoma 0.5 0.3 0.67
Allergic Rhinitis (Hay Fever) 2.8 2.8
Allergies 2.5 1.5 0.67
Allergy to milk products 2 0.8 1.5
Alopecia (Hair Loss) 1 1
Alzheimer's disease 2.3 3.8 -0.65
Amyotrophic lateral sclerosis (ALS) Motor Neuron 2 1 1
Ankylosing spondylitis 4 1.5 1.67
Anorexia Nervosa 0.3 1.6 -4.33
Antiphospholipid syndrome (APS) 2.5 2.5
Asthma 1.5 1 0.5
Atherosclerosis 0 2 0
Atrial fibrillation 1.4 2.3 -0.64
Autism 9.3 6 0.55
Barrett esophagus cancer 0.5 -0.5
benign prostatic hyperplasia 0.5 0.5
Biofilm 3 3
Bipolar Disorder 1.3 1 0.3
Brain Trauma 1 -1
Cancer (General) 0.5 3 -5
Carcinoma 2.8 1.3 1.15
Celiac Disease 3.5 1.3 1.69
Cerebral Palsy 1 1 0
Chronic Fatigue Syndrome 8.5 4.5 0.89
Chronic Kidney Disease 2.8 0.7 3
Chronic Lyme 1 -1
Chronic Obstructive Pulmonary Disease (COPD) 2.5 0.5 4
Chronic Urticaria (Hives) 2.5 2 0.25
Coagulation / Micro clot triggering bacteria 2.3 1 1.3
Colorectal Cancer 5.3 0.1 52
Constipation 2 0.5 3
Coronary artery disease 1.1 0 0
COVID-19 9.6 11.3 -0.18
Crohn's Disease 7.3 3 1.43
cystic fibrosis 1.5 1 0.5
deep vein thrombosis 1.5 1 0.5
Depression 11.8 4.3 1.74
Dermatomyositis 0.5 0.5
Eczema 1.5 3 -1
Endometriosis 2.8 0.5 4.6
Epilepsy 2.5 1.1 1.27
Fibromyalgia 2.6 3 -0.15
Functional constipation / chronic idiopathic constipation 5.8 4.5 0.29
gallstone disease (gsd) 1.3 0.5 1.6
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 2 0.5 3
Generalized anxiety disorder 2.5 1 1.5
giant cell arteritis 0.5 -0.5
Glioblastoma 0.5 -0.5
Gout 0 0
Graves' disease 0.8 0.5 0.6
Halitosis 0.5 0.5 0
Hashimoto's thyroiditis 1 0.5 1
Hidradenitis Suppurativa 0.5 0.5
High Histamine/low DAO 3 0 0
hypercholesterolemia (High Cholesterol) 1 1
hyperglycemia 0.5 0.8 -0.6
hypertension (High Blood Pressure 1.8 5 -1.78
Hypothyroidism 0.5 -0.5
Hypoxia 0.8 0.8
IgA nephropathy (IgAN) 5.5 -5.5
Inflammatory Bowel Disease 7 4.8 0.46
Insomnia 1 1 0
Intelligence 1.5 1 0.5
Intracranial aneurysms 0.8 0.8
Irritable Bowel Syndrome 5 4.3 0.16
Liver Cirrhosis 3.3 2 0.65
Long COVID 8.9 3 1.97
Low bone mineral density 0.5 -0.5
Lung Cancer 1.5 0 0
Mast Cell Issues / mastitis 1 0 0
ME/CFS with IBS 2 0.5 3
ME/CFS without IBS 3.5 1.5 1.33
Menopause 1 1
Metabolic Syndrome 7.8 6.8 0.15
Mood Disorders 12.8 4.8 1.67
multiple chemical sensitivity [MCS] 1.5 1.5
Multiple Sclerosis 4.3 6.5 -0.51
Multiple system atrophy (MSA) 2 0 0
neuropathic pain 1.5 -1.5
Neuropathy (all types) 0.5 0.5 0
neuropsychiatric disorders (PANDAS, PANS) 1.5 1.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 2.5 1.2 1.08
NonCeliac Gluten Sensitivity 0.5 0.5 0
Obesity 6.8 3.3 1.06
obsessive-compulsive disorder 6.8 3.1 1.19
Osteoarthritis 4 0 0
Osteoporosis 2 0.5 3
pancreatic cancer 1 1
Parkinson's Disease 5.8 5.4 0.07
Polycystic ovary syndrome 2.8 1.5 0.87
Postural orthostatic tachycardia syndrome 0.5 0 0
Premenstrual dysphoric disorder 0.3 -0.3
primary biliary cholangitis 1 -1
Psoriasis 3 3.3 -0.1
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 4.8 3 0.6
Rosacea 0 1 0
Schizophrenia 4.3 1 3.3
scoliosis 0 0 0
Sjögren syndrome 2.8 1.9 0.47
Sleep Apnea 0 1.5 0
Slow gastric motility / Gastroparesis 1.5 1.5
Small Intestinal Bacterial Overgrowth (SIBO) 1.5 1.5
Stress / posttraumatic stress disorder 2.8 2 0.4
Systemic Lupus Erythematosus 4.8 1 3.8
Tic Disorder 1.5 1 0.5
Tourette syndrome 0.5 -0.5
Type 1 Diabetes 4 2.5 0.6
Type 2 Diabetes 8.3 7.3 0.14
Ulcerative colitis 3.5 6.3 -0.8
Unhealthy Ageing 5.5 1.2 3.58
Vitiligo 1.5 0.8 0.88

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [34.204.176 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [34.204.176 ]